 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- ALG-020576 / Aligos Therap, ALG-020572 / Aligos Therap
Incorporation of novel ASO chemistries significantly improves the potency and durability of HBV ASOs in the AAV-HBV mouse model (Poster Area) - Mar 16, 2022 - Abstract #EASLILC2022EASL_ILC_1761;
Novel modifications of ALG-020576 significantly improved the in vivo depth and durability of HBsAg knockdown. Further investigations combining these chemistries are ongoing.
- ALG-020576 / Aligos Therap
[VIRTUAL] BEST-IN-CLASS ANTISENSE OLIGONUCLEOTIDES AGAINST HEPATITIS B VIRUS: NEXT GENERATION BRIDGED NUCLEIC ACID CHEMISTRIES SIGNIFICANTLY INCREASE IN VIVO EFFICACY AND REDUCE HEPATOTOXICITY IN MICE () - Oct 21, 2021 - Abstract #AASLD2021AASLD_1052;
These results suggest that application of these novel nucleotide chemistries could lead to best-in-class anti-HBV ASOs. Currently, novel ASO therapeutics using this approach are being advanced into clinical trials for CHB.
- ALG-020572 / Aligos Therap
[VIRTUAL] DEVELOPMENT OF A BEST-IN-CLASS HBV ASO, ALG-020572, FOR THE TREATMENT OF CHRONIC HEPATITIS B () - Oct 11, 2020 - Abstract #AASLD2020AASLD_84;
Compared with a single ASO, a 1:1 combination of ALG-020572 and ALG-020576 offers enhanced in vivo potency, better genotypic coverage, a higher resistance barrier and a greater capacity to retain efficacy after HBV genome integration events. This regimen can also be combined with other anti-HBV agents.